Not Found

Find information on medical topics, symptoms, drugs, procedures, news and more, written for the health care professional.

Metachromatic Leukodystrophy

(Sulfatide Lipidosis)

By Lee M. Sanders, MD, MPH, Associate Professor of Pediatrics, Stanford University

Click here for
Patient Education

Metachromatic leukodystrophy is a sphingolipidosis, an inherited disorder of metabolism, caused by arylsulfatase A deficiency, which causes progressive paralysis and dementia resulting in death by age 10 yr.

For more information, see Table Sphingolipidosis.

In metachromatic leukodystrophy, arylsulfatase A deficiency causes metachromatic lipids to accumulate in the white matter of the CNS, peripheral nerves, kidney, spleen, and other visceral organs; accumulation in the nervous system causes central and peripheral demyelination. Numerous mutations exist; patients vary in age at onset and speed of progression.

The infantile form is characterized by progressive paralysis and dementia usually beginning before age 4 yr and resulting in death about 5 yr after onset of symptoms.

The juvenile form manifests between 4 yr and 16 yr of age with gait disturbance, intellectual impairment, and findings of peripheral neuropathy. Contrary to the infantile form, deep tendon reflexes are usually brisk. There is also a milder adult form.

Diagnosis of metachromatic leukodystrophy is suggested clinically and by findings of decreased nerve conduction velocity; it is confirmed by detecting enzyme deficiency in WBCs or cultured skin fibroblasts. (Also see testing for suspected inherited disorders of metabolism.)

There is no effective treatment for metachromatic leukodystrophy.